Announcement on the company’s expected daily related transactions in 2026
Securities code: 603108 Securities abbreviation: Runda Medical Announcement number: Lin 2025-061 Convertible bond code: 113588 Convertible bond abbreviation: Runda convertible bonds
Shanghai Runda Medical Technology Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
This routine related transaction needs to be submitted to the shareholders' meeting of Shanghai Runda Medical Technology Co., Ltd. (hereinafter referred to as the "Company" and "Listed Company") for review.
This daily related transaction will not cause the company to become dependent on related parties, and will not affect the independence of the listed company.
1. Basic situation of daily related transactions
(1) Estimation and execution of previous daily related transactions (unit: RMB 10,000, excluding tax) Estimated for 2025
1-10, 2025
Amount and related transaction type in 2025 Actual occurrence in month of 2025
Related Persons Actual Issues from January to October Estimated Amount Amount (Unreviewed
Calculate the difference in student amount)
The big reason Guizhou Runda Kangyi Medical Technology Co., Ltd. 50.00 29.98
Guorun Medical Supply Chain Services (Shanghai) has
6,900.00 6,677.51
Ltd.
Hebei Runda Kangtai Medical Technology Co., Ltd. 2,100.00 550.82
Sichuan Runda Hongwang Medical Technology Co., Ltd. 5,000.00 3,193.81
Suzhou Runying Medical Equipment Co., Ltd. 600.00 36.04
Procurement from related parties
Yunnan Sailis Biotechnology Co., Ltd. 1,700.00 1,629.86
Purchase goods
Shanghai General Runda Medical Technology Co., Ltd. 2,200.00 1,554.10
Fujian Furui Medical Technology Co., Ltd. 50.00 2.30
Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
12,700.00 4,827.27 Note 1 Company
Hangzhou Huihao Information Technology Co., Ltd. 3,000.00 341.01 Note 1
Subtotal 34,300.00 18,842.70
Sales to related parties Fujian Furui Medical Technology Co., Ltd. 500.00 56.13
Goods sold by Guorun Medical Supply Chain Services (Shanghai) 45,000.00 46,842.49
Ltd.
Hebei Runda Kangtai Medical Technology Co., Ltd. 7,200.00 2,002.62 Note 1 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
3,000.00 990.59Company
Shanghai General Runda Medical Technology Co., Ltd. 500.00 153.82 Suzhou Runying Medical Equipment Co., Ltd. 1,000.00 -
Yunnan Sailis Biotechnology Co., Ltd. 300.00 115.49 Guangxi Liurun Medical Technology Co., Ltd. 500.00 266.19 Guizhou Runda Kangyi Medical Technology Co., Ltd. 100.00 41.89 Sichuan Runda Hongwang Medical Technology Co., Ltd. 100.00 -
Subtotal 58,200.00 50,469.22
Guorun Medical Supply Chain Services (Shanghai) has
1,000.00 160.52 Co., Ltd.
Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
200.00 75.67Company
Provided labor services to related parties Suzhou Runying Medical Equipment Co., Ltd. 120.00 89.79 Guizhou Runda Kangyi Medical Technology Co., Ltd. 22.00 1.13 Hebei Runda Kangtai Medical Technology Co., Ltd. 50.00 302.68 Shanghai General Runda Medical Technology Co., Ltd. 130.00 -
Fujian Furui Medical Technology Co., Ltd. 100.00 2.46
Subtotal 1,622.00 632.25
Acceptance of services from related parties Shanghai General Runda Medical Technology Co., Ltd. 10.00 53.40 Services provided Subtotal 10.00 53.40 Borrowing from related parties Yunnan Sailis Biotechnology Co., Ltd. 120.00 91.20 Profits incurred
Subtotal 120.00 91.20
information
Total 94,252.00 70,088.77
Note 1: Business needs have changed, and the actual amount incurred above was generated between January and October, less than one year.
(2) Estimated amount and category of this daily related transaction (unit: RMB 10,000, excluding tax)
The estimated amount this time
1-10, 2025
Related-party transactions expected to occur in 2025
Related person Actual payment amount from January to October Amount (no amount difference has been audited)
The big reason Guorun Medical Supply Chain Services (Shanghai) has
2,000.00 6,677.51 Note 1 Co., Ltd.
Hebei Runda Kangtai Medical Technology Co., Ltd. 400.00 550.82 Purchase from related parties Sichuan Runda Hongwang Medical Technology Co., Ltd. 3,600.00 3,193.81 Purchase goods Suzhou Runying Medical Equipment Co., Ltd. 100.00 36.04 Yunnan Sailis Biotechnology Co., Ltd. 2,100.00 1,629.86 Shanghai General Runda Medical Technology Co., Ltd. 1,300.00 1,554.10 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. 8,000.00 4,827.27 Note 1 Company
Hangzhou Huihao Information Technology Co., Ltd. 5,000.00 341.01 Note 1
Subtotal 22,500.00 18,810.42
Fujian Furui Medical Technology Co., Ltd. 100.00 56.13 Guorun Medical Supply Chain Services (Shanghai) has
51,000.00 46,842.49 Note 1 Co., Ltd.
Hebei Runda Kangtai Medical Technology Co., Ltd. 2,600.00 2,002.62 Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
Sales to related parties 1,300.00 990.59 Company
Goods for sale
Shanghai General Runda Medical Technology Co., Ltd. 300.00 153.82 Suzhou Runying Medical Equipment Co., Ltd. 100.00 - Yunnan Sailis Biotechnology Co., Ltd. 100.00 115.49 Guangxi Liurun Medical Technology Co., Ltd. 600.00 266.19
Subtotal 56,100.00 50,427.33
Guorun Medical Supply Chain Services (Shanghai) has
600.00 160.52 Co., Ltd.
Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
150.00 75.67Company
Provide labor services to related parties Suzhou Runying Medical Equipment Co., Ltd. 100.00 89.79 Hebei Runda Kangtai Medical Technology Co., Ltd. 100.00 302.68 Shanghai General Runda Medical Technology Co., Ltd. 200.00 - Fujian Furui Medical Technology Co., Ltd. 50.00 2.46 Hangzhou Huihao Information Technology Co., Ltd. 100.00 19.58
Subtotal 1,300.00 650.70
Guorun Medical Supply Chain Services (Shanghai) has
Accept related parties 50.00 5.31 Co., Ltd.
Services provided
Subtotal 50.00 5.31
Borrowing from related parties Yunnan Sailisi Biotechnology Co., Ltd. 120.00 91.20 Profits incurred
Subtotal 120.00 91.20
information
Total 80,070.00 69,984.96
Note 1: Due to changes in business needs and procurement channels, the actual amount incurred above was generated between January and October, less than one year.
2. Introduction to related parties and related relationships
(1) Guorun Medical Supply Chain Services (Shanghai) Co., Ltd. (hereinafter referred to as "Guorun Supply Chain")
- Basic situation
Company name: Guorun Medical Supply Chain Services (Shanghai) Co., Ltd.
Unified social credit code: 91310105MA1FW0G339
Date of establishment: November 12, 2015
Company address: Room 5A, Building 4, No. 1398 Kaixuan Road, Changning District, Shanghai
Registered capital: RMB 100 million
Legal representative: Wu Bin
The shareholding structure is:
Guorun Supply Chain is a holding subsidiary of Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd., a company in which the company participates.
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 2,444,867,400, total liabilities were RMB 1,710,486,400, and net assets were RMB 734,381,000; operating income in 2024 was RMB 4,217,356,800, and net profit was RMB 178,832,600. (This data has been audited)
Related relationship with listed companies: Guorun Supply Chain is a holding subsidiary of Sinopharm Holding Runda Medical Device Development (Shanghai) Co., Ltd., a company in which the company participates. Mr. Liu Hui, the company's vice chairman and general manager, and Mr. Hu Zhenning, director and deputy general manager, concurrently serve as directors of Guorun Supply Chain.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(2) Yunnan Sailis Biotechnology Co., Ltd. (hereinafter referred to as "Yunnan Sailis")
- Basic situation
Company Name: Yunnan Sailis Biotechnology Co., Ltd.
Unified social credit code: 91530112587393412Q
Date of establishment: January 10, 2012
Company address: 13th Floor, Building 1, Haiyuan Fortune Center, No. 390 Haiyuan Middle Road, High-tech Zone, Kunming City, Yunnan Province Registered capital: RMB 7.6923 million
Legal representative: Yang Hao
Major shareholder: Ruan Qihui
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 371.7059 million, total liabilities were RMB 21.7515 million, and net assets were RMB 349.9544 million; operating income in 2024 was RMB 239.7766 million, and net profit was RMB 35.6175 million. (This data has been audited)
Related relationships with listed companies: The company holds 35% of the equity of Yunnan Sailis, and Ms. Lu Xiaoyan, the company’s director and deputy general manager, is also a director of Yunnan Sailis.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(3) Sichuan Runda Hongwang Medical Technology Co., Ltd. (hereinafter referred to as "Sichuan Runda Hongwang")
- Basic situation
Company name: Sichuan Runda Hongwang Medical Technology Co., Ltd.
Unified social credit code: 91510100MA62Q1NP51
Date of establishment: January 25, 2017
Company address: No. 605, 6th Floor, Building 2, No. 88 Keyuan South Road, Chengdu High-tech Zone
Registered capital: RMB 30 million
Legal representative: Shen Bihua
Major shareholder: Chengdu Tongxin Hongwang Medical Technology Partnership (Limited Partnership)
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 71.7163 million, total liabilities were RMB 53.5126 million, and net assets were RMB 18.2037 million; operating income in 2024 was RMB 77.3033 million, and net profit was RMB -189,000. (This data has been audited)
Related relationships with listed companies: The company holds 22% of the equity of Sichuan Runda Hongwang. Mr. Hu Zhenning, the company’s director and deputy general manager, and Ms. Lu Xiaoyan, the company’s director and deputy general manager, concurrently serve as directors of Sichuan Runda Hongwang.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(4) Guizhou Runda Kangyi Medical Technology Co., Ltd. (hereinafter referred to as "Guizhou Runda")
- Basic situation
Company Name: Guizhou Runda Kangyi Medical Technology Co., Ltd.
Unified social credit code: 91520191MA6DW5A87R
Date of establishment: March 16, 2017
Company address: No. 18, Floor 1, Building B4, Qunsheng Century Plaza, Lot 9, Central Business District, Jinyang Street, Guanshanhu District, Guiyang City, Guizhou Province
Registered capital: RMB 30 million
Legal representative: Liu Ting
Major shareholder: Guizhou Meiguanquan Investment Consulting Co., Ltd.
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 155.6012 million, total liabilities were RMB 100.0917 million, and net assets were RMB 55.5095 million; operating income in 2024 was RMB 150.8559 million, and net profit was RMB 3.2585 million. (This data has been audited)
Related relationship with listed companies: The company holds 10% equity of Guizhou Runda, and Mr. Hu Zhenning, the company’s director and deputy general manager, is also a director of Guizhou Runda.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(5) Fujian Furui Medical Technology Co., Ltd. (hereinafter referred to as "Fujian Furui")
- Basic situation
Company Name: Fujian Furui Medical Technology Co., Ltd.
Unified social credit code: 91350100315437581G
Date of establishment: January 4, 2015
Company address: South side of the 2nd floor, Building 2, No. V-03, Cangshan Science and Technology Park, Baihutingpuxia Road, Cangshan District, Fuzhou City, Fujian Province
Registered capital: RMB 10 million
Legal representative: Qu Zhijun
Major shareholder: Qu Zhijun
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 63.6084 million, total liabilities were RMB 20.0104 million, and net assets were RMB 43.598 million; operating income in 2024 was RMB 51.832 million, and net profit was RMB 131,100. (This data has been audited)
Related relationship with listed companies: The company holds 40% equity of Fujian Furui. Mr. Hu Zhenning, the company’s director and deputy general manager, and Ms. Lu Xiaoyan, the company’s director and deputy general manager, also serve as directors of Fujian Furui.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(6) Shanghai General Runda Medical Technology Co., Ltd. (hereinafter referred to as "General Runda")
- Basic situation
Company Name: Shanghai General Runda Medical Technology Co., Ltd.
Unified social credit code: 9141010079678388X4
Date of establishment: December 12, 2006
Company address: Room 3001-1, No. 575 Wusong Road, Hongkou District, Shanghai
Registered capital: RMB 100 million
Legal representative: Mei Mei
Major shareholder: Henan General Pharmaceutical and Health Industry Co., Ltd.
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 102.3707 million, total liabilities were RMB 27.2034 million, and net assets were RMB 75.1673 million; operating income in 2024 was RMB 59.3599 million, and net profit was -25.6093 million yuan. (This data has been audited)
Related relationships with listed companies: The company holds 49% of the equity of GM Runda, and Ms. Lu Xiaoyan, the company’s director and deputy general manager, also serves as a director of GM Runda.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(7) Runda Rongmai (Hangzhou) Medical Technology Co., Ltd. (hereinafter referred to as "Runda Rongmai")
- Basic situation
Company name: Runda Rongmai (Hangzhou) Medical Technology Co., Ltd.
Unified social credit code: 91330103MA2J0XYC21
Date of establishment: August 24, 2020
Company address: Room 1504-1, Building 1, Haozhang Building, Gongshu District, Hangzhou City, Zhejiang Province
Registered capital: RMB 10 million
Legal representative: Xue Ying
Major shareholder: Xue Ying
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 115.5185 million, total liabilities were RMB 104.0185 million, and net assets were RMB 11.500 million; operating income in 2024 was RMB 68.5293 million, and net profit was RMB 1.0885 million. (This data has been audited)
Related relationship with listed companies: The company holds 40% equity of Runda Rongmai, and Mr. Hu Zhenning, the company’s director and deputy general manager, also serves as a director of Runda Rongmai.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(8) Hebei Runda Kangtai Medical Technology Co., Ltd. (hereinafter referred to as "Hebei Runda")
- Basic situation
Company Name: Hebei Runda Kangtai Medical Technology Co., Ltd.
Unified social credit code: 91130102MA08L76U1Y
Date of establishment: May 26, 2017
Company address: Room 2301-2305, Building C, Tianshan Galaxy Plaza, No. 358 Yuhua East Road, Shijiazhuang High-tech Zone Registered capital: RMB 10 million
Legal representative: Guo Zhanjun
Major shareholder: Chen Hong
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 304.7568 million, total liabilities were RMB 270.5352 million, and net assets were RMB 34.2216 million; operating income in 2024 was RMB 192.6337 million, and net profit was RMB 6.9899 million. (This data has been audited)
Related relationship with listed companies: The company holds 20% equity of Hebei Runda, and Mr. Hu Zhenning, the company’s director and deputy general manager, also serves as a director of Hebei Runda.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(9) Suzhou Runying Medical Equipment Co., Ltd. (hereinafter referred to as "Suzhou Runying")
- Basic situation
Company name: Suzhou Runying Medical Equipment Co., Ltd.
Unified social credit code: 91320594MA1MTQLM1F
Date of establishment: September 5, 2016
Company address: West side of 5th floor, No. 38 Jujin Road, Taiping Street, Xiangcheng District, Suzhou City
Registered capital: RMB 30 million
Legal representative: Liao Jianwei
Major shareholder: Ningbo Ruichen Investment Partnership (Limited Partnership)
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 419.2419 million, total liabilities were RMB 215.9739 million, and net assets were RMB 203.2680 million; operating income in 2024 was RMB 441.2956 million, and net profit was RMB 30.8738 million. (This data has been audited)
Related relationships with listed companies: Hangzhou Runda Medical Management Co., Ltd., a wholly-owned subsidiary of the company, holds 35% of the equity of Suzhou Runying. Mr. Hu Zhenning, the company’s director and deputy general manager, also serves as a director of Suzhou Runying.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(10) Guangxi Liurun Medical Technology Co., Ltd. (hereinafter referred to as "Guangxi Liurun")
- Basic situation
Company name: Guangxi Liurun Medical Technology Co., Ltd.
Unified social credit code: 91450100MA5L2DMP6W
Date of establishment: April 6, 2017
Company address: No. 7, Guokai Avenue, Nanning City
Registered capital: RMB 100 million
Legal representative: Pan Yingxi
Major shareholder: Guangxi Liuyao Group Co., Ltd.
The main business is a comprehensive service provider for medical laboratories, providing various in vitro diagnostic products and related technologies and other services to medical laboratories.
As of December 31, 2024, total assets were RMB 187.5861 million, total liabilities were RMB 40.2881 million, and net assets were RMB 147.2981 million; operating income in 2024 was RMB 99.3496 million, and net profit was RMB 8.2462 million. (This data has been audited)
Related relationships with listed companies: The company holds 49% of the equity of Guangxi Liurun. Mr. Hu Zhenning, the company’s director and deputy general manager, and Ms. Lu Xiaoyan, the director and deputy general manager, concurrently serve as directors of Guangxi Liurun.
Analysis of the execution status and performance ability of similar related-party transactions in the previous period: Similar related-party transactions in the previous period were performed as agreed, and no related party default occurred. The aforementioned related parties have good credit status and have the ability to perform contracts.
(11) Hangzhou Huihao Information Technology Co., Ltd. (hereinafter referred to as "Hangzhou Huihao")
- Basic situation
Company Name: Hangzhou Huihao Information Technology Co., Ltd.
Unified social credit code: 91330103MA2KJYFJ6K
Date of establishment: August 24, 2021
Company address: Room 1308, SDIC Building, No. 398 Shaoxing Road, Gongshu District, Hangzhou City, Zhejiang Province
Registered capital: RMB 1.202 million
Legal representative: Zhang Chengxu
Major shareholders: Shanghai Internal and External Information Technology Partnership (Limited Partnership), Shanghai Aiyi Sensing Information Technology Partnership (Limited Partnership)
The main business is the independent research and development of technical tools such as clinical natural language processing engines, medical knowledge reasoning, and clinical automated machine learning platforms.
As of December 31, 2024, total assets were RMB 49.9108 million, total liabilities were RMB 58.9141 million, and net assets were RMB -9.0033 million; operating income in 2024 was RMB 7.7342 million, and net profit was RMB -46.0317 million. (This data has been audited)
Related relationships with listed companies: Hangzhou Huizhong Diagnostic Technology Co., Ltd., a wholly-owned subsidiary of the company, holds 16.64% of the equity of Hangzhou Huihao. The company’s director, Mr. Zhang Chengxu, concurrently serves as the director and general manager of Hangzhou Huihao.
Analysis of the execution status and performance capabilities of similar related-party transactions in the previous period: There was no related-party default in the related-party transactions that occurred in the previous period. The aforementioned related parties have good credit status and have the ability to perform contracts.
3. Main contents and pricing policies of related-party transactions
The company's daily related transactions expected to occur with related parties in 2026 are mainly related transactions such as selling goods and providing services, purchasing goods and receiving services to meet the company's normal operations.
All related transactions between the company and its related parties are conducted under the principles of equality, voluntariness, fairness and justice. The pricing of related transactions is fair and does not harm the interests of the company and shareholders, especially small and medium-sized shareholders. All relevant transactions have fulfilled the necessary decision-making and approval procedures, and the necessity of the transactions and the fairness of pricing have all met relevant requirements.
4. Purpose of related-party transactions and their impact on listed companies
The above-mentioned related-party transactions are transactions required for the company's normal business operations, which are conducive to the development and execution of the company's daily business operations and are conducive to the company's sustainable and stable operations.
The pricing policies and pricing basis of these related-party transactions are determined in accordance with the general commercial principles of openness, fairness and impartiality. The transaction price is based on the principle of fair market price. It is a complete market behavior and does not affect the company's independence or the company's ability to continue operating. The company's main business or sources of income and profits do not entirely rely on such related transactions. The above-mentioned transactions will not have a significant impact on the company's assets and profits and losses, and will not harm the interests of the company and other shareholders, especially small and medium-sized shareholders.
5. Internal decision-making procedures for implementation
On December 15, 2025, the fourth meeting of the independent directors of the fifth board of directors in 2025 reviewed and approved the "Proposal on the Company's Estimation of Daily Related Transactions in 2026" by unanimous vote. The independent directors issued an audit opinion: The company's expected daily related transactions in 2026 are necessary for the company's business development to ensure the normal development of the company's production and operation activities. The prices of related transactions are fair and executed in accordance with market prices, and there is no behavior that harms the interests of the company and shareholders, especially small and medium shareholders. It is agreed to be submitted to the 27th meeting of the company's fifth board of directors for review, and related directors should abstain from voting.
On December 16, 2025, the 27th meeting of the company’s fifth board of directors reviewed and approved the “Proposal on the Company’s Estimation of Daily Related Transactions in 2026”. Related directors Zhang Chengxu, Liu Hui, Hu Zhenning and Lu Xiaoyan have abstained from voting, and the remaining non-related directors have voted to agree to the motion, which still needs to be submitted to the company's shareholders' meeting for review.
This transaction is still subject to the approval of the shareholders' meeting, and related parties with an interest in the related transaction will give up the right to vote on the resolution at the shareholders' meeting.
6. Documents for reference
Resolution of the 27th meeting of the fifth board of directors of Shanghai Runda Medical Technology Co., Ltd.
Resolution of the fourth special meeting of independent directors of the fifth board of directors of Shanghai Runda Medical Technology Co., Ltd. in 2025
Announcement is hereby made.
Board of Directors of Shanghai Runda Medical Technology Co., Ltd.
December 16, 2025